- Home
- AGIO
as 11-06-2025 3:52pm EST
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 2.4B | IPO Year: | 2013 |
| Target Price: | $59.33 | AVG Volume (30 days): | 567.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.41 - $62.58 | Next Earning Date: | 10-30-2025 |
| Revenue: | $44,791,000 | Revenue Growth: | 36.26% |
| Revenue Growth (this year): | 25.57% | Revenue Growth (next year): | 153.24% |
Stock Insider Trading Activity of Agios Pharmaceuticals Inc. (AGIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gheuens Sarah | AGIO | Chief Medical Officer | Oct 30 '25 | Sell | $43.81 | 200 | $8,762.00 | 61,727 | |
| Gheuens Sarah | AGIO | Chief Medical Officer | Oct 27 '25 | Sell | $43.92 | 3,302 | $145,023.84 | 61,727 | |
| Scadden David | AGIO | Director | Oct 8 '25 | Sell | $41.00 | 200 | $8,200.00 | 17,603 | |
| Scadden David | AGIO | Director | Sep 30 '25 | Sell | $40.00 | 200 | $8,000.00 | 17,603 | |
| Jones Cecilia | AGIO | Chief Financial Officer | Sep 26 '25 | Sell | $36.77 | 3,651 | $134,247.27 | 33,870 | |
| Washburn Theodore James Jr. | AGIO | Principal Accounting Officer | Sep 5 '25 | Sell | $36.87 | 8,546 | $315,091.02 | 868 | |
| Scadden David | AGIO | Director | Aug 27 '25 | Sell | $40.00 | 200 | $8,000.00 | 17,603 |
Latest Agios Pharmaceuticals Inc. News
AGIO Breaking Stock News: Dive into AGIO Ticker-Specific Updates for Smart Investing
Simply Wall St.
20 days ago
Evaluating Agios Pharmaceuticals After 16% Rally and Positive Early Data on Mitapivat in Sickle Cell Disease
MT Newswires
21 days ago
Agios Pharmaceuticals Says EU Panel Gave Positive Opinion For Pyrukynd For Adults With Thalassemia
Business Wire
21 days ago
Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia
GlobeNewswire
21 days ago
Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
GlobeNewswire
2 months ago
Atavistik Bio Expands Leadership Team with Appointment of Susan Pandya, M.D., as Chief Medical Officer
Simply Wall St.
2 months ago
FDA Review Delay for PYRUKYND Might Change the Case for Investing in Agios Pharmaceuticals (AGIO)
Zacks
2 months ago
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
MT Newswires
4 months ago
Agios Pharmaceuticals Insider Sold Shares Worth $627,198, According to a Recent SEC Filing
Compare AGIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AGIO Agios Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.